Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial

• DOI: 10.1016/j.dld.2022.07.008
• Publication Date: 2022-07-28T02:40:49Z
• Authors: Clélia Coutzac; Frederic Bibeau; Meher Ben Abdelghani; Thomas Aparicio; Romain Cohen; Elodie Coquan; Olivier Dubreuil; Ludovic Evesque; François Ghiringh...; Stefano Kim; Samuel Lesourd; Cindy Neuzillet; Jean-Marc Phelip; Guillaume Piessen; Philippe Rochigneux; Emmanuelle Samalin; Emilie Soularue; Yann Touchefeu; David Tougeron; Aziz Zaanan; Christelle de la ...
• Keywords: MSI/dMMR; [SDV]Life Sciences [q-bio]; 610; Immune checkpoint inhibitor; Colorectal cancer; DNA Mismatch Repair; 3. Good health; Perioperative immunotherapy; [SDV] Life Sciences [q-bio]; 03 medical and health sciences; Antineoplastic Agents, Immunological; 0302 clinical medicine; Endometrial cancer; Neoplasms; Humans; Immunologic Factors; Microsatellite Instability; Immunotherapy; Prospective Studies; Gastric cancer; Colorectal Neoplasms; Immune Checkpoint Inhibitors

BackgroundImmune checkpoint inhibitors (ICI) targeting Programmed death-1 (PD-1) have shown their efficacy in advanced MSI/dMMR (microsatellite instability/deficient mismatch repair) tumors. The status predicts clinical response to ICI. promising results evaluating ICI localized tumors neoadjuvant setting need be confirmed solid aim of the IMHOTEP trial is assess anti-PD-1 treatment regarding pathological complete rate.MethodsThis study a prospective, multicenter, phase II including 120 patients with carcinomas suitable for curative surgery. A single dose pembrolizumab will administered before surgery planned 6 weeks later. Primary objective evaluate according tumor response. Secondary objectives are safety, recurrence-free survival and overall survival. Ancillary studies molecular immunological biomarkers predicting response/resistance First patient was enrolled December 2021.DiscussionThe one first investigating perioperative agnostic setting. Assessing mandatory improve patient's outcomes. translational program explore potential biomarker our understanding immune escape this